262 related articles for article (PubMed ID: 25971211)
1. Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition.
Fisher ML; Adhikary G; Xu W; Kerr C; Keillor JW; Eckert RL
Oncotarget; 2015 Aug; 6(24):20525-39. PubMed ID: 25971211
[TBL] [Abstract][Full Text] [Related]
2. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C
Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
[TBL] [Abstract][Full Text] [Related]
3. Tissue transglutaminase induces Epithelial-Mesenchymal-Transition and the acquisition of stem cell like characteristics in colorectal cancer cells.
Ayinde O; Wang Z; Griffin M
Oncotarget; 2017 Mar; 8(12):20025-20041. PubMed ID: 28223538
[TBL] [Abstract][Full Text] [Related]
4. PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.
Karicheva O; Rodriguez-Vargas JM; Wadier N; Martin-Hernandez K; Vauchelles R; Magroun N; Tissier A; Schreiber V; Dantzer F
Oncotarget; 2016 Sep; 7(39):64109-64123. PubMed ID: 27579892
[TBL] [Abstract][Full Text] [Related]
5. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells.
Kumar A; Xu J; Sung B; Kumar S; Yu D; Aggarwal BB; Mehta K
Breast Cancer Res; 2012 Jan; 14(1):R4. PubMed ID: 22225906
[TBL] [Abstract][Full Text] [Related]
6. Transglutaminase is a tumor cell and cancer stem cell survival factor.
Eckert RL; Fisher ML; Grun D; Adhikary G; Xu W; Kerr C
Mol Carcinog; 2015 Oct; 54(10):947-58. PubMed ID: 26258961
[TBL] [Abstract][Full Text] [Related]
7. Blocking TG2 attenuates bleomycin-induced pulmonary fibrosis in mice through inhibiting EMT.
Wang K; Zu C; Zhang Y; Wang X; Huan X; Wang L
Respir Physiol Neurobiol; 2020 May; 276():103402. PubMed ID: 32006666
[TBL] [Abstract][Full Text] [Related]
8. Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.
Kerr C; Szmacinski H; Fisher ML; Nance B; Lakowicz JR; Akbar A; Keillor JW; Lok Wong T; Godoy-Ruiz R; Toth EA; Weber DJ; Eckert RL
Oncogene; 2017 May; 36(21):2981-2990. PubMed ID: 27941875
[TBL] [Abstract][Full Text] [Related]
9. Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer.
Agnihotri N; Kumar S; Mehta K
Breast Cancer Res; 2013 Feb; 15(1):202. PubMed ID: 23673317
[TBL] [Abstract][Full Text] [Related]
10. Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathways.
Kumar S; Donti TR; Agnihotri N; Mehta K
Int J Cancer; 2014 Jun; 134(12):2798-807. PubMed ID: 24477458
[TBL] [Abstract][Full Text] [Related]
11. Transglutaminase Interaction with α6/β4-Integrin Stimulates YAP1-Dependent ΔNp63α Stabilization and Leads to Enhanced Cancer Stem Cell Survival and Tumor Formation.
Fisher ML; Kerr C; Adhikary G; Grun D; Xu W; Keillor JW; Eckert RL
Cancer Res; 2016 Dec; 76(24):7265-7276. PubMed ID: 27780825
[TBL] [Abstract][Full Text] [Related]
12. The transglutaminase 2 cancer cell survival factor maintains mTOR activity to drive an aggressive cancer phenotype.
Chen X; Adhikary G; Newland JJ; Xu W; Ma E; Naselsky W; Eckert RL
Mol Carcinog; 2023 Jan; 62(1):90-100. PubMed ID: 35848131
[TBL] [Abstract][Full Text] [Related]
13. Cancer-associated Fibroblasts induce epithelial-mesenchymal transition
Jia C; Wang G; Wang T; Fu B; Zhang Y; Huang L; Deng Y; Chen G; Wu X; Chen J; Pan Y; Tai Y; Liang J; Li X; Hu K; Xie B; Li S; Yang Y; Chen G; Zhang Q; Liu W
Int J Biol Sci; 2020; 16(14):2542-2558. PubMed ID: 32792856
[TBL] [Abstract][Full Text] [Related]
14. Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target.
Agnihotri N; Mehta K
Amino Acids; 2017 Mar; 49(3):425-439. PubMed ID: 27562794
[TBL] [Abstract][Full Text] [Related]
15. Role of Tissue Transglutaminase Catalytic and Guanosine Triphosphate-Binding Domains in Renal Cell Carcinoma Progression.
Ulukan B; Bihorac A; Sipahioglu T; Kiraly R; Fesus L; Telci D
ACS Omega; 2020 Nov; 5(43):28273-28284. PubMed ID: 33163811
[TBL] [Abstract][Full Text] [Related]
16. Role of tissue transglutaminase 2 in the acquisition of a mesenchymal-like phenotype in highly invasive A431 tumor cells.
Lin CY; Tsai PH; Kandaswami CC; Chang GD; Cheng CH; Huang CJ; Lee PP; Hwang JJ; Lee MT
Mol Cancer; 2011 Jul; 10():87. PubMed ID: 21777419
[TBL] [Abstract][Full Text] [Related]
17. Competitive Binding of Magnesium to Calcium Binding Sites Reciprocally Regulates Transamidase and GTP Hydrolysis Activity of Transglutaminase 2.
Jeong EM; Lee KB; Kim GE; Kim CM; Lee JH; Kim HJ; Shin JW; Kwon MA; Park HH; Kim IG
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31991788
[TBL] [Abstract][Full Text] [Related]
18. Elongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion.
Ashour AA; Gurbuz N; Alpay SN; Abdel-Aziz AA; Mansour AM; Huo L; Ozpolat B
J Cell Mol Med; 2014 Nov; 18(11):2235-51. PubMed ID: 25215932
[TBL] [Abstract][Full Text] [Related]
19. Transglutaminase 2 Regulates Self-renewal and Stem Cell Marker of Human Colorectal Cancer Stem Cells.
Kang S; Oh SC; Min BW; Lee DH
Anticancer Res; 2018 Feb; 38(2):787-794. PubMed ID: 29374703
[TBL] [Abstract][Full Text] [Related]
20. A novel regulatory role for tissue transglutaminase in epithelial-mesenchymal transition in cystic fibrosis.
Nyabam S; Wang Z; Thibault T; Oluseyi A; Basar R; Marshall L; Griffin M
Biochim Biophys Acta; 2016 Sep; 1863(9):2234-44. PubMed ID: 27234323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
